This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This KCNQ1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 4-33 amino acids from the N-terminal region of human KCNQ1.
KCNQ1
Reaktivität: Human
WB, IHC, IP, IF, ICC, AA
Wirt: Maus
Monoclonal
N37A-10 (Formerly S37A-10)
unconjugated
Applikationshinweise
WB: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Haltbarkeit
6 months
Target
KCNQ1
(Potassium Voltage-Gated Channel, KQT-Like Subfamily, Member 1 (KCNQ1))
Andere Bezeichnung
KCNQ1
Hintergrund
This gene encodes a voltage-gated potassium channel required for the repolarization phase of the cardiac action potential. The gene product can form heteromultimers with two other potassium channel proteins, KCNE1 and KCNE3. Mutations in this gene are associated with hereditary long QT syndrome (also known as Romano-Ward syndrome), Jervell and Lange-Nielsen syndrome and familial atrial fibrillation. The gene is located in a region of chromosome 11 that contains a number of contiguous genes, which are abnormally imprinted in cancer and the Beckwith-Wiedemann syndrome. This gene is also imprinted, with preferential expression from the maternal allele in some tissues, excluding cardiac muscle. Alternatively spliced transcripts encoding distinct isoforms have been described.